Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor
Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998
To the Editor.—Psoriasis is a chronic and often disabling skin condition that has stimulated the marketing and use of many approved and unapproved topical over-the-counter medications. Since the early 1990s, one of these over-the-counter medications, SKIN-CAP in spray, shampoo, or cream formulation (manufactured by Cheminova Laboratories International, SA, Madrid, Spain), has been sold in the United States by several distributors. The sole active ingredient in this product has been reported to be pyrithione zinc, which also is found in dandruff shampoos and is approved for the treatment of seborrheic dermatitis. SKIN-CAP is not approved by the US Food and Drug Administration (FDA) for the treatment of psoriasis or other dermatoses. Nonetheless, the use of SKIN-CAP for psoriasis has been widespread, and preliminary findings from a blinded clinical study of psoriasis have shown efficacy (C. Crutchfield, MD, E. Lewis, MD, B. Zelickson, MD, oral communication, May 13, 1997). To determine if other active ingredients were present, we examined SKIN-CAP spray formulation by several analytical methods, including capillary electrophoresis (CE) and tandem mass spectrometry (MS/MS).
Pittelkow MR, Benson LM, Naylor S, Tomlinson AJ. Detection of Corticosteroid in an Over-the-counter Product. JAMA. 1998;280(4):327-328. doi:10-1001/pubs.JAMA-ISSN-0098-7484-280-4-jbk0722